Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

University of Michigan117 enrolled

Overview

This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes. It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation. Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

117

Conditions

Atrial Fibrillation

Interventions

Metformin immediate release will be initiated at 250 milligrams (mg) daily (orally), and increased as tolerated to 2000 mg daily over a four week period. If a patient is unable to tolerate a dose increase they will return to their last tolerated dose after omitting one days dosing. 0 to Six weeks after the initiation of drug the patient will undergo (standard of care) ablation with the intent of achieving rhythm control. Participants will stay on the metformin 12 months after the ablation. In addition, all participants will receive education on lifestyle changes and exercise which are standard of care as well as have a discussion with their treating electrophysiologist and receive a handout.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Body Mass Index (BMI) \>25 kilograms / square meter (kg/m2) with plan for rhythm control of atrial fibrillation by catheter ablation * All subjects must be able to understand and willing to sign a written informed consent document. Exclusion Criteria: * Individuals who are already taking metformin or other antidiabetic medications, including insulin * Known diabetes * Known allergy or Food and Drug Administration (FDA)-labeled contraindication to taking metformin (estimated glomerular filtration rate (eGFR)\<30 millilitres per minute (mL/min)/1.73 square meters (m2), hypersensitivity to metformin, acute or chronic metabolic acidosis) * Patients taking carbonic anhydrase inhibitors * eGFR below 30 mL/min per 1.73 m2 or other clinical diagnosis of advanced renal disease * Acute or chronic metabolic acidosis (serum bicarbonate \<22 milliequivalents per liter (mEq/L)) * History of significant alcohol use (\>2 drinks/day on average) * History of hepatic dysfunction (serum bilirubin 1.5 times greater than ULN) * History of New York Heart Association (NYHA) Class III or IV heart failure * Pregnancy or nursing

Outcomes

Primary Outcomes

Freedom from recurrent atrial arrhythmias by 12 months after a single ablation to eliminate AF

There will be a 3 month blanking period after ablation during which recurrent atrial arrhythmias will not contribute to the primary endpoint.

Time frame: 12 months after ablation

Secondary Outcomes

Time to recurrence of atrial fibrillation after a 3 month blanking period of ablation

Time frame: up to 1 year after after ablation

Freedom from recurrent atrial arrhythmias at 1 year after ablation after the blanking period of 3 months

Time frame: 6 months after ablation

Freedom from recurrent atrial arrhythmias at 6 months after repeat ablation

Time frame: 6 months after a repeated ablation

Atrial Fibrillation Severity Score (AFSS)

There are a total of 19 questions (parts A,B, and C) in this questionnaire. This collects information regarding the participants atrial fibrillation. It includes seven questions for subjects to report severity of symptoms (i.e. palpitations, shortness of breath at rest/physical activity, exercise intolerance, fatigue at rest, and lightheadedness/dizziness, chest pain or pressure) on a Likert scale from 0 (subject did not have this symptom) to 5 (symptom bothers subject a great deal).

Time frame: up to 12 months after ablation

Percent change in weight at 3 months after ablation

Time frame: 3 months after ablation

Percent change in weight at 6 months after ablation

Time frame: 6 months after ablation

Percent change in hemoglobin A1c at 6 months after ablation

Time frame: 6 months after ablation

Percent change in hemoglobin A1C at 12 months after ablation

Time frame: 12 months after ablation

Incidence of major procedural complications

Complications include but are not limited to major bleeding, vascular injury, myocardial perforation, stroke, and mortality.

Time frame: up to 30 days

Atrial Fibrillation related morbidity during follow-up

During follow-up visits information will be collected regarding Emergency department visits and hospital admissions due to AF, Transient Ischemic Attack (TIA)/cerebrovascular accident (CVA), and mortality. These will be collected as total numbers between groups.

Time frame: up to approximately 1 year after ablation

Burden of Atrial Fibrillation assessed by AliveCOR Kardia Devices

Time frame: 6 months after ablation

Burden of Atrial Fibrillation assessed by AliveCOR Kardia Devices

Time frame: 1 year after ablation

Burden of Atrial Fibrillation assessed by AliveCOR Kardia Devices

Time frame: 3 months after ablation

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes